JB/CALL/GILEAD SCIENCES/100/0.05/20.06.25 | Market Closed - Swiss Exchange 16:20:00 28/06/2024 BST | ||
| 0.04 CHF | -20.00% |
|
| Current month | +100.00% | ||
| 1 month | +100.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.04 | -20.00% |
| 26/06/24 | 0.05 | -16.67% |
| 21/06/24 | 0.06 | +100.00% |
Delayed Quote Swiss Exchange
Last update June 28, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Bank Julius Bär |
| GIZGJB | |
| ISIN | CH1317201551 |
| Date issued | 17/01/2024 |
| Strike | 100 $ |
| Maturity | 20/06/2025 (357 Days) |
| Parity | 20 : 1 |
| Emission price | 0.23 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.25 CHF |
|---|---|
| Lowest since issue | 0.02 CHF |
| Spread | 0.01 CHF |
| Spread % | 25.00% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.83
USD
Average target price
82.97
USD
Spread / Average Target
+20.54%
- Stock Market
- Warrants
- GIZGJB Warrant
